REGULATED PRESS RELEASE published on 12/05/2024 at 08:02, 16 days 21 hours ago NFL BIOSCIENCES VALIDATES THE INDUSTRIALIZATION OF NFL-101 FOR SMOKING CESSATION
BRIEF published on 11/18/2024 at 17:50, 1 month 3 days ago NFL Biosciences Presents NFL-101 at Tobacco Congress NFL Biosciences Smoking Cessation NFL-101 Tobaccology Disruptive Mechanism
REGULATED PRESS RELEASE published on 10/18/2024 at 08:00, 2 months 3 days ago NFL BIOSCIENCES: LEADERSHIP TEAM PREPARING THE NEXT STAGES IN ITS DEVELOPMENT
REGULATED PRESS RELEASE published on 10/08/2024 at 08:00, 2 months 13 days ago NFL BIOSCIENCES: EFFICACY VALIDATED THROUGH UPDATED ANALYSES FROM CESTO II FOR SMOKING CESSATION. SIGNIFICANT REDUCTION IN CRAVING. STRONG COMMERCIAL POTENTIAL CONFIRMED.
BRIEF published on 09/27/2024 at 17:50, 2 months 24 days ago NFL BIOSCIENCES: 2024 First-Half Business and Earnings Update Capital Increase NFL-101 Phase 3 Trial NFL-301 Clinical Developments
REGULATED PRESS RELEASE published on 09/27/2024 at 17:45, 2 months 24 days ago NFL BIOSCIENCES: 2024 FIRST-HALF BUSINESS AND EARNINGS UPDATE NFL Biosciences reports 2024 first-half business and earnings update, showcasing advancements in smoking cessation drug candidate NFL-101 and alcohol consumption drug candidate NFL-301 NFL Biosciences Smoking Cessation Botanical Drugs 2024 First-half Earnings Alcohol Consumption
REGULATED PRESS RELEASE published on 09/09/2024 at 17:45, 3 months 12 days ago NFL BIOSCIENCES: PARTICIPATION CALENDAR PHARMA EVENTS AND INSTITUTIONAL INVESTORS
REGULATED PRESS RELEASE published on 07/15/2024 at 08:00, 5 months 6 days ago NFL BIOSCIENCES: CESTO II STUDY RESULTS
BRIEF published on 06/17/2024 at 11:05, 6 months 4 days ago NFL BIOSCIENCES Publishes Study on NFL-101 Mechanism of Action Smoking Cessation NFL-101 Scientific Research ACS Chemical Neuroscience Mechanism Of Action
REGULATED PRESS RELEASE published on 06/17/2024 at 11:00, 6 months 4 days ago NFL BIOSCIENCES: Scientific publication of the study on the mechanism of action of NFL-101 conducted by the CEA in ACS Chemical Neuroscience Announcement regarding geographic restrictions on document distribution United States United Kingdom Announcement Geographic Restrictions Document Distribution
Published on 12/21/2024 at 01:30, 1 day 3 hours ago Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 1 day 3 hours ago iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 1 day 5 hours ago Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/20/2024 at 23:30, 1 day 5 hours ago Boron One Announces Extension to Early Warrant Exercise Incentive Program
Published on 12/21/2024 at 00:51, 1 day 4 hours ago Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/20/2024 at 19:10, 1 day 9 hours ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/20/2024 at 18:56, 1 day 10 hours ago CPI PROPERTY GROUP – Progress on Key Initiatives
Published on 12/20/2024 at 18:00, 1 day 11 hours ago ARYZTA AG Announces New Board Technology Committee
Published on 12/21/2024 at 12:17, 16 hours 51 minutes ago AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 1 day 11 hours ago Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 1 day 11 hours ago Disclosure of trading in own shares from 16/12/2024 to 20/12/2024
Published on 12/20/2024 at 14:00, 1 day 15 hours ago Safran: Woodward Signs Agreement to Acquire Safran’ s Electromechanical Actuation Business based in North America
Published on 12/19/2024 at 18:30, 2 days 10 hours ago Share capital decrease by way of treasury shares cancellation